# 1 Survival trends among people living with human immunodeficiency virus on antiretroviral

- 2 treatment in two rural districts in Ghana
- 3

## 4 Authors

- 5 Eugene Sackeya<sup>1,2</sup>, Martin Muonibe Beru<sup>1,3</sup>, Richard Nomo Angmortey<sup>1,3</sup>, Kingsley Boakye<sup>1</sup>,
- 6 Musah Baatira<sup>1,8</sup>, Mohammed Sheriff Yakubu<sup>1,6</sup>, Douglas Aninng Opoku<sup>5,7</sup>, Aliyu Mohammed<sup>1,</sup>
- 7 Nana Kwame Ayisi-Boateng<sup>9</sup>, Daniel Boateng<sup>1,4</sup>, Emmanuel Kweku Nakua<sup>1</sup>, and Anthony
- 8 Kweku Edusei<sup>10</sup>
- 9

## 10 Affiliations

- <sup>1</sup>Department of Epidemiology and Biostatistics, School of Public Health, Kwame Nkrumah
- 12 University of Science and Technology, Kumasi, Ghana.
- <sup>13</sup> <sup>2</sup>Tatale District Hospital, Tatale, Northern Region, Ghana.
- <sup>14</sup> <sup>3</sup>Tamale Teaching Hospital, Tamale Metropolitan, Tamale Ghana.
- <sup>4</sup>Julius Global Health, Julius Centre for Health Sciences and Primary Care, University Medical
- 16 Centre, Utrecht, The Netherlands.
- <sup>5</sup>Allen Clinic, Family Health Services, Kumasi, Ghana.
- 18 <sup>6</sup>Nursing and Midwifery Training College, Nalerigu-Ghana.
- 19 <sup>7</sup>Department Of Global Health and Internal Health, School of Public Health, Kwame Nkrumah
- 20 University of Science and Technology, Kumasi, Ghana.
- <sup>8</sup>St. Joseph's Midwifery Training College, Jirapa, Ghana.
- <sup>9</sup>Department Of Medicine, School of Medicine and Dentistry, Kwame Nkrumah University of
- 23 Science and Technology, Kumasi, Ghana
- <sup>10</sup>Department of Health Promotion, School of Public Health, Kwame Nkrumah University of
- 25 Science and Technology, Kumasi, Ghana.
- 26

## 27 Corresponding Author

28 Eugene Sackeya: <u>mcsackeya@gmail.com</u>

29

30

### 31 Abstract

**Background**: The human immunodeficiency virus (HIV) has caused a lot of havoc since the early 32 33 1970s, affecting 37.6 million people worldwide. The 90-90-90 treatment policy was adopted in Ghana in 2015 with the overall aim to end new infections by 2030, and to improve the life 34 expectancy of HIV seropositive individuals. With the scale-up of Highly Active Antiretroviral 35 Therapy (HAART), the lifespan of People Living with HIV (PLWH) on antiretrovirals (ARVs) is 36 expected to improve. In rural districts in Ghana, little is known about the survival probabilities of 37 PLWH on ARVs hence, this study was conducted to estimate the survival trends of PLWH on 38 ARVs for the periods between 2016 to 2020. 39

40 Methods: A retrospective evaluation of data gathered across ARV centers within Tatale and 41 Zabzugu districts in Ghana from 2016 to 2020 among PLWH on ARVs. The census technique was 42 employed and a total of 261 participants were recruited for the study. The data was analyzed using 43 STATA software version 16.0. Lifetable analysis and Kaplan-Meier graph were used to assess the 44 survival probabilities. "Stptime" per 1000 person-years and the competing risk regression was 45 used to evaluate mortality rates and risk of mortality.

46 **Results:** The cumulative survival probability was 0.8847 (95% CI: 0.8334-0.9209). The overall 47 mortality rate was 51.89 (95% CI: 36.89-72.97) per 1000 person-years. WHO stage III and IV 48 [AHR: 4.25 (95%CI: 1.6-9.71) p = 0.001] as well as age group (50<sup>+</sup> years) [AHR: 5.02 (95% CI: 49 1.78-14.13) p=0.002] were associated with mortality.

50 Conclusion: Survival probabilities is high among the population of PLWH in Ghana with 51 declining mortality rates. Clinicians should provide critical attention and care to patients at HIV 52 WHO stages III and IV and intensify HIV screening at all entry points since early diagnosis is 53 associated with high survival probabilities.

54

55 Keywords: Antiretroviral; Competing risk; Ghana; HIV; PLHIV; Survival trends

- 56
- 57
- 58
- 59

### 60 Background

The human immunodeficiency virus (HIV), the organism responsible for acquired immune deficiency syndrome (AIDS) has caused a lot of havoc to individuals and families since its outbreak in the early 1970s [1,2]. HIV has affected 37.6 million people worldwide as of 2020, with an estimated 27.4 million people accessing antiretroviral (ARVs) therapy globally [3].

The majority affected by this HIV pandemic live in low and middle-income countries (LMICs) 65 with 20.6 million (55%) of all cases from eastern and southern Africa, while 4.7 million (13%) are 66 in western and central Africa [3,4]. In Ghana, about 342,307 people are living with HIV (PLWH) 67 and of these, 77% of them are receiving lifesaving highly active antiretroviral therapy (HAART) 68 [5]. The therapeutic value of antiretroviral therapy (ART) for PLWH is undeniable and early 69 initiation of ART reduces morbidity and mortality. It is evident that when HIV replication is 70 71 suppressed, patients have significant improvement in immunologic status, as seen by higher clusters of differentiation 4 (CD4) counts, lower AIDS-related morbidity and death, and, in many 72 73 cases, a return to a normal or near-normal quality of life [6]. The advantages of early ART include 74 a reduction in not just classic AIDS-related problems, but also end-stage organ damage as well as 75 non-AIDS-defining malignancies [6].

ART administration was introduced in Ghana in June 2003 as part of a comprehensive care 76 package including voluntary counseling and testing (VCT), prevention of mother-to-child 77 transmission (PMTCT) of HIV, and the treatment and management of sexually transmitted 78 79 infections (STIs) [7]. However, only PLWH whose CD4 count was  $\leq$  350 or classified as being in WHO stages III and IV were initiated on ARVs [7,8]. Owing to the global impact of the HIV 80 pandemic exceeding all expectations, with a mortality peak of 1.9 million deaths in 2006 to 0.95 81 82 million in 2017 [9], the World Health Organization (WHO) and its partners adopted an ambitious 83 treatment target, dubbed the 90-90-90 agenda which was reviewed in 2020 to 95-95-95. In this policy, 95% of PLWH should know their status, 95% of those who know their status should be on 84 ARVs and 95% of those on ARVs should achieve viral suppression [4]. This treatment policy is 85 in line with sustainable development goal three which emphasizes the need for good health and 86 well-being of all people by 2030 with HIV being one of the significant indicators [11]. 87

Ghana, a WHO member state adopted this policy in 2015 with efforts made to increaseaccessibility to HIV counseling and testing services, provision of ARVs for all those living with

HIV and enhanced evaluation of effectiveness of ARVs through regular viral load assessment at
regular intervals at no cost to the clients [5]. As of 2019 in Ghana, 58% of PLWH know their HIV
status, of this number, 77% of them are receiving ARVs and 68% of those receiving ARVs have
their viral load suppressed [5,12].

During the early 1980s, to be diagnosed with HIV in Ghana was synonymous with a death sentence, however, with the scale-up of HAART, more PLWH are now receiving the lifesaving ARVs with the aim of improving their life expectancy [13]. In Ghana there is limited data on survival trends of PLWH. This study therefore sought to estimate the survival trends of PLWH on ARVs for the periods between 2016 to 2020, the mortality rate and the associated risk factors.

99

## 100 Methods

#### 101 Study Design

The study was a retrospective evaluation of data from antiretroviral therapy (ART) sites in tworural districts in Ghana (Zabzugu and Tatale Districts).

104

## 105 Study Setting

106 The study was conducted in the Zabzugu and Tatale districts of the northern region of the Republic of Ghana. These two districts were purposively selected based on their active involvement in ART 107 108 in the region. Participants were drawn from four ART centers at the Zabzugu district hospital (ZDH), Tatale district hospital (TDH), Kpalbutabu Health Center -Tatale and Nakpali Health 109 Center -Zabzugu. With the capitals of the two districts being Zabzugu and Tatale respectively, 110 they share a border with Togo in the east, to the north with Saboba, to the west Yendi, and to the 111 112 south, Wulensi. Zabzugu District covers an area of 1,100.1 square kilometer and Tatale Sangule district covers an area of about 1,130 square kilometers [14,15]. 113

114

### **Study Population**

The study population included PLWH, 13 years old and above, in the Tatale and Zabzugu districts who were diagnosed and enrolled on ARVs. The study participants were PLWH who were diagnosed not earlier than 2016 or were diagnosed earlier but started ARVs in 2016 through to 2020. PLWH less than 13 years at the time of registration due to their dependency on parents and

- 120 care givers likely to influence adherance and those who were transferred from districts outside the121 two districts for lack of adequate information were excluded.
- 122

## 123 Sampling Technique

The census sampling technique was used for the selection of the research participants. The study 124 participants included all PLWH who were diagnosed with HIV from 2016 to 2020 and followed 125 for varying number of years, but not exceeding five years. A sample size of 261 participants were 126 considered for this study. The sample size constituted the entire number of PLWH who started 127 their treatment from 2016 to 2020. A total of 275 PLHIV were registered within the period, while 128 14 participants were excluded from the study as a result of transfers, under age (< 13 years) and 129 incomplete information. Most of the participants entered the study at different entry points but 31st 130 December 2021 was the administrative censoring date for all participants. 131

132

## 133 Variables description

## 134 Dependent variable:

The main outcome variable was the survival probabilities of PLWH on ARVs. This predicted the chance of a participant being alive following the initiation to ARVs during the study period. The secondary outcomes included the mortality rate and the risk factors for mortality.

138

## 139 Independent variables:

The study used eleven (11) independent variables. These included the type of regimen the person 140 was on, which is either a efavirenz-based combination or a dolutegravir-based combination, 141 comorbidity/coinfection defined as any other medical condition that co-existed with HIV or AIDS 142 143 during diagnosis, HIV status disclosure refers to disclosing one's HIV status to anyone other than a healthcare provider, and enrolment on the National Health Insurance Scheme (NHIS). The 144 remaining variables included the participant's marital status, WHO HIV stages (I, II, III, and IV), 145 client's locality or area of residence, client's health facility where ARVs is received, gender and 146 religion. 147

- 148
- 149
- 145
- 150

#### 151 Data Collection and Management

Data collection was conducted from 1st July 2022 to 31st August 2022 using a standard checklist 152 153 by two public health nurses and a postgraduate student of Epidemiology and Biostatistics. This was done by reviewing existing medical records including the patient's ARVs folder, the pharmacy 154 logbook, the ARVs logbook, and the viral load register. Two different data collection officers 155 collected the same data set and incomplete forms were returned to be completed and those that 156 were not completed for lack of adequate information were dropped. The data was validated by 157 comparing the data from the two research assistants to ensure accuracy and consistency. After 158 cleaning, the data was stored in a hard drive and also in Google drive for future use and protection. 159

160

## 161 Data Analysis

Data was analyzed using the STATA statistical software version 16.0. Descriptive statistics were 162 used to describe the baseline characteristics of participants including the socio-demographic and 163 the clinical characteristics. For the person-time computation, the date of administrative censorship 164 (December 31, 2021) was considered as the last date for all persons who were still alive and 165 166 receiving treatment. For the assessment of the survival probabilities, lifetable analysis was done alongside the display of a survival function using a Kaplan-Meier graph to assess variations in 167 168 survival among subgroups. The overall mortality rate was calculated using stptime per 1000 person years. The stptime command computed and tabulated the person-time and the incidence rate. The 169 170 subgroup mortality rates were calculated using stptime adjusting for the subgroup per 1000 person years. To examine the association between baseline factors and mortality, the Competing risk 171 172 regression model was used. Statistical significance was set at p-value <0.05 at a confidence interval of 95%. Variables (both significant and insignificant at the Univariate level) that were 173 174 deemed to be important based on previous studies [15,16] were included in the multivariable 175 analysis.

176

### 177 Ethical consideration

Ethical clearance was granted by the Committee for Human Research, Publication and Ethics of the Kwame Nkrumah University of Science and Technology with reference number CHRPE/AP/287/22. Participants informed consent was not taken since this study involved a review of secondary data from hospital medical records and the patients were not available at the

time of the data collection. This was explained in the application for the ethical clearance and

183 participants' consent was waived by the ethics committee. All the study data that were collected

184 were completely anonymized.

- 185
- 186 **Results**

## 187 Socio-Demographic Characteristics of Participants

The study participants who were in the age category of 30 to 39 years were 41.0% with the median age (interquartile range) of 35 (14) years. More than half (66.28%) of study participants were females while a little over one third (42.53%) were Christians. Approximately 51.34% resided in the Tatale Sanguli district even though 58.62% received their medications from the Zabzugu district. Those who had no formal education constituted 72.03% of the participants while 61.30% were non-skilled workers. Approximately 89.7% were married and 90.42% of them were registered with the National Health Insurance Scheme (NHIS) (Table 1).

195

|                        | Zabzugu District | <b>Tatale District</b> | Total (%)  |  |
|------------------------|------------------|------------------------|------------|--|
| Varaiable              | Frequency (%)    | Frequency (%)          |            |  |
| Age (years)            |                  |                        |            |  |
| 13-19                  | 2 (0.8)          | 10 (3.8)               | 12 (4.6)   |  |
| 20-29                  | 32 (12.3)        | 31 (11.9)              | 63 (24.2)  |  |
| 30-39                  | 74 (28.4)        | 33 (12.6)              | 107 (41.0) |  |
| 40-49                  | 28 (10.7)        | 14 (5.4)               | 42 (16.1)  |  |
| <b>50</b> <sup>+</sup> | 17 (6.5)         | 20 (7.6)               | 37 (14.1)  |  |
| Median age (IQR)       | 35 (14)          |                        |            |  |
| Gender                 |                  |                        |            |  |
| Male                   | 59 (22.6)        | 29 (11.1)              | 88 (33.7)  |  |
| Female                 | 94 (36.0)        | 79 (30.3)              | 173 (66.3) |  |
| Religion               |                  |                        |            |  |
| Christain              | 50 (19.2)        | 61 (23.1)              | 111 (42.5) |  |
| Muslim                 | 64 (24.5)        | 17 (6.5)               | 81 (31.1)  |  |
| Traditional            | 39 (14.9)        | 30 (11.5)              | 69 (26.4)  |  |
| District-of-Residences |                  |                        |            |  |
| Zabzugu district       | 118 (45.2)       | 1 (0.4)                | 119 (45.6) |  |
| Tatale district        | 29 (11.1)        | 105 (40.2)             | 134 (51.3) |  |
| Other districts        | 6 (2.3)          | 2 (0.8)                | 8 (3.1)    |  |
| Educational Level      |                  |                        |            |  |

## **196 Table 1: Socio-demographic characteristics of participants**

| Formal education            | 36 (13.8)  | 37 (14.2) | 73 (28.0)  |
|-----------------------------|------------|-----------|------------|
| No formal education         | 117 (44.8) | 71 (27.2) | 188 (72.0) |
| Occupation                  |            |           |            |
| Unemployed                  | 50 (19.2)  | 30 (11.5) | 80 (30.7)  |
| Skilled worker              | 12 (4.6)   | 9 (3.5)   | 21 (8.1)   |
| None skilled worker         | 91 (34.9)  | 69 (26.4) | 160 (61.3) |
| Marital Status              |            |           |            |
| Never Married               | 10 (3.8)   | 17 (6.5)  | 27 (10.3)  |
| Ever Married                | 143 (54.8) | 91 (34.9) | 234 (89.7) |
| NHIS Status                 |            |           |            |
| <b>Registered with NHIS</b> | 139 (53.3) | 97 (37.1) | 236 (90.4) |
| Not registered with NHIS    | 14 (5.4)   | 11 (4.2)  | 25 (9.6)   |

197 NHIS = National Health Insurance, ZDH = Zabzugu District Hospital, TDH = Tatale District Hospital, IQR:
198 Interquartile range

## 200 Clinical characteristics of the study participants

Table 2 presents results of clinical charcteristics of the study participants. Majority (64.0%) were diagnosed at WHO stage I and 42.91% had disclosed their HIV status to another person other than the healthcare provider. Most of the participants (83.14%) were on Efavirenz-based Combination while 52.87% were alive and traceable at the time of the study.

|                         | Zabzugu District | Tatale District |            |
|-------------------------|------------------|-----------------|------------|
| Variable                | Frequency (%)    | Frequency (%)   | Total (%)  |
| WHO HIV Stage           |                  |                 |            |
| Stage I                 | 105 (40.2)       | 62 (23.8)       | 167 (64.0) |
| Stage II                | 15 (5.7)         | 25 (9.6)        | 40 (15.3)  |
| Both stage III & IV     | 33 (12.6)        | 21 (8.0)        | 54 (20.6)  |
| HIV status disclosure   |                  |                 |            |
| Disclosed               | 70 (26.8)        | 42 (16.1)       | 112 (42.9) |
| Not disclosed           | 83 (31.8)        | 66 (25.3)       | 149 (57.1) |
| Combined ARV type       |                  |                 |            |
| EBC                     | 129 (49.4)       | 88 (33.7)       | 217 (83.1) |
| DBC                     | 24 (9.2)         | 20 (7.7)        | 44 (16.9)  |
| ARV's treatment outcome |                  |                 |            |
| Dead                    | 23 (8.8)         | 10 (3.6)        | 33 (12.6)  |
| Alive                   | 86 (33.0)        | 52 (19.9)       | 138 (52.9  |
| LTFU                    | 44 (16.9)        | 46 (17.6)       | 90 (34.5)  |

#### 219 Table 1: Clinical Characteristics of Study Participants

220 WHO = World Health Organization, HIV = Human Immune Virus, ARV's = Antiretrovirals, n = Sample Size, LTFU

221 = Loss to Follow Up, DBC = Dolutegravir Based Combination, EBC = Efavirenz Based Combination.

222

## 223 Five-Year Trend of Survival Probabilities

A total of 635.981 person-years with 2.17 median person years of follow-up was contributed by the 261 participants. In the first year of follow-up, 15 mortalities were recorded giving a survival probability of 0.9376 (95% CI: 0.8987-0.9619) for the period. After three years of follow-up, the cumulative mortality was 32 and a survival probability of 0.8337 (95% CI: 0.7704-0.8809). With decline in mortalities over the years, the overall mortality at the end of the fifth years was 33 and a survival probability of 0.8049 (95% CI: 0.7145-0.8693) (table 3).

- 230 231
- Table 2: survival probabilities **Total person-years** 635.981 Median person years of follow-up 2.17 Years No at-risk Deaths Iterations Survival Probability (95% CI) 0-1 0.9376 (0.8987-0.9619) 261 15 41 1-2 205 10 56 0.8847 (0.8334-0.9209) 7 2-3 35 0.8337 (0.7704-0.8809) 139

| 3-4 | 97 | 0 | 40 | 0.8337 | (0.7704-0.8809) |
|-----|----|---|----|--------|-----------------|
| 4-5 | 57 | 1 | 56 | 0.8049 | (0.7145-0.8693) |

232 CL = Confidence Interval, NO = Number

233

234 Overall, the Kaplan-Meier survival curve revealed that the majority of fatalities occurred in the first to third years after starting ARVs, thus 15, 10 & 7 respectively. Even though the overall 235 cumulative survival probability for the five-year study period was 0.8049, those who were 236 237 diagnosed at the WHO stages I and II had a higher survival probability as shown in figure 1 and 238 so was for women and those in the age group of 13-29 years. Patients who did not disclose their HIV status had higher survival probability than those who disclosed their status but this trend 239 changed after two years of follow-up where the survival probabilities of those who disclosed their 240 status improved (Figure1). 241



244 Figure 1: Kaplan Meier's Survival Estimates

#### **245** Five-Year Mortality Rates among PLWH on ARVs.

- Thirty-three (12.64%) participants died during the study period. The total person years for the fiveyear period was 635.98 person years with the overall mortality rate of 51.89 (95% CI: 36.89-72.97) per 1000 person years. Mortality rates were higher above the overall rate among participants 30 years and above, 55.22 (95% CI: 37.60-81.10) per 1000 person years and males 68.65 (95% CI: 41.39-113.87) per 1000 person years. The mortality rate was almost even among those who disclosed their HIV status and those who did not with 53.60 (95% CI: 31.75- 90.51) per 1000 person-years and 50.69 (95% CI: 32.34-79.48) per 1000 person-years respectively. WHO stage III
- and IV recorded the highest mortality rate of 123.75 (95% CI: 73.29-208.95) per 1000 person-
- 254 years.
- 255 In the univariate competing risk regression analysis, age was statistically significant and associated
- with mortality. The hazard of mortality was 3.28 times higher among those aged 50 and above
- [HR: 3.28; 95% CI: 1.29-8.33, p=0.013] and after adjusting for confounders in the multivariable
- analysis [AHR: 5.02; 95% CI: 1.78-14.13, p=0.002]. WHO stage was statistically significant, the
- hazard of mortality was 3.51 times higher among those diagnosed at WHO stage III & IV [HR:
- 260 3.51; 95% CI: 1.67-7.38, p=0.001] and the same was the case after adjusting for confounders
- 261 [AHR: 4.63; 95% CI: 1.91-11.18, p=0.001], however, we cannot rule out region and marital status
- as factors influencing mortality among PLWH (Table 4).

|      |  | Mortality Rate per  | Univariate Analysis  | Multivariable Analysis   |
|------|--|---|--|--|
| Dead | PY   | 1000 PY (95%CI)   | SHR (95% CI) P-<br>Value   | ASHR (95% CI) P-Value  |
| 33   | 635.98   | 51.89 (36.89-72.97)   |  |  |
|      |  |   |  |  |
| 1    | 23.57  | 42.42 (5.98-301.15)   | 0.92 (0.12-7.09) 0.940   | 6.33 (0.78-51.08) 0.083  |
| 6    | 141.58   | 42.38 (19.04-94.33)   | 1.12 (0.40-3.12) 0.827   | 1.72 (0.54-5.50) 0.358   |
| 9    | 275.51   | 32.67 (16.10-62.78)   | 1  | 1  |
| 8    | 111.96   | 71.46 (35.74-142.88)  | 2.31 (0.90-5.95) 0.082   | 1.77 (0.60-5.18) 0.298   |
| 9    | 83.36  | 107.96 (56.17-207.49)   | 3.28 (1.29-8.33) 0.013   | 5.02 (1.78-14.13) 0.002  |
|      |  |   |  |  |
| 18   | 417.48   | 43.12 (27.16-68.43)   | 1  | 1  |
| 15   | 218.50   | 68.65 (41.39-113.87)  | 1.70 (0. 85-3.37) 0.132  | 1.06 (0.44-2.51) 0.893   |
|      |  |   |  |  |
| 6    | 185.79   | 32.29 (14.51-71.88)   | 1  | 1  |
| 13   | 255.69   | 50.84 (29.52-87.56)   | 1.38 (0.52-3.67) 0.516   | 2.08 (0.73-5.96) 0.173   |
| 14   | 194.50   | 71.98 (42.63-121.53)  | 2.20 (0.83-5.79) 0.111   | 2.74 (0.94-7.99) 0.065   |
|      | Dead<br>33<br>1<br>6<br>9<br>8<br>9<br>18<br>15<br>6<br>13<br>14 | Dead       PY         33       635.98         1       23.57         6       141.58         9       275.51         8       111.96         9       83.36         18       417.48         15       218.50         6       185.79         13       255.69         14       194.50 | Dead       PY       Mortality Rate per<br>1000 PY (95%CI)         33       635.98       51.89 (36.89-72.97)         1       23.57       42.42 (5.98-301.15)         6       141.58       42.38 (19.04-94.33)         9       275.51       32.67 (16.10-62.78)         8       111.96       71.46 (35.74-142.88)         9       83.36       107.96 (56.17-207.49)         18       417.48       43.12 (27.16-68.43)         15       218.50       68.65 (41.39-113.87)         6       185.79       32.29 (14.51-71.88)         13       255.69       50.84 (29.52-87.56)         14       194.50       71.98 (42.63-121.53) | Dead         PY         Mortality Rate per<br>1000 PY (95%CI)         Univariate Analysis<br>SHR (95% CI)         P-<br>P-<br>Value           33         635.98         51.89 (36.89-72.97)            1         23.57         42.42 (5.98-301.15)         0.92 (0.12-7.09)         0.940           6         141.58         42.38 (19.04-94.33)         1.12 (0.40-3.12)         0.827           9         275.51         32.67 (16.10-62.78)         1         0.92           8         111.96         71.46 (35.74-142.88)         2.31 (0.90-5.95)         0.082           9         83.36         107.96 (56.17-207.49)         3.28 (1.29-8.33)         0.013           18         417.48         43.12 (27.16-68.43)         1         1.32           6         185.79         68.65 (41.39-113.87)         1.70 (0.85-3.37)         0.132           6         185.79         32.29 (14.51-71.88)         1         1.32           13         255.69         50.84 (29.52-87.56)         1.38 (0.52-3.67)         0.516           14         194.50         71.98 (42.63-121.53)         2.20 (0.83-5.79)         0.111 |

# 263 Table 3: Mortality rates and their determinants

| 9  | 150.62  | 59.75 (31.09-114.84)  | 1  | 1   |
|----|---|---|--|---|
| 24 | 485.36  | 49.45 (33.14-73.77)   | 1.02 (0.47-2.19) 0.963   | 0.58 (0.23-1.45) 0.247  |
|    |   |   |  |   |
| 6  | 191.11  | 31.40 (14.10-69.88)   | 1  | 1   |
| 3  | 53.49   | 56.08 (18.09-173.89)  | 1.96 (0.49-7.79) 0.337   | 2.41 (0.43-13.42) 0.315   |
| 24 | 391.38  | 61.32 (41.10-91.49)   | 2.06 (0.85-4.99) 0.111   | 2.23 (0.82-6.07) 0.117  |
|    |   |   |  |   |
| 1  | 59.83   | 16.71 (2.35-118.66)   | 1  | 1   |
| 32 | 576.15  | 55.54 (39.28-78.54)   | 3.91 (0.54-28.19) 0.177  | 5.16 (0.97-27.50) 0.054   |
|    |   |   |  |   |
| 3  | 59.79   | 50.17 (16.18-155.56)  | 1  | 1   |
| 30 | 576.19  | 52.07 (36.40-74.47)   | 1.05 (0.31-3.56) 0.931   | 1.36 (0.40-4.61) 0.620  |
|    |   |   |  |   |
| 10 | 234.80  | 42.59 (22.92-79.15)   | 1  | 1   |
| 23 | 401.18  | 57.33 (38.10-86.27)   | 1.66 (0.79-3.48) 0.181   | 2.05 (0.75-5.60) 0.161  |
|    | 9<br>24<br>6<br>3<br>24<br>1<br>32<br>3<br>30<br>10<br>23 | 9       150.62         24       485.36         6       191.11         3       53.49         24       391.38         1       59.83         32       576.15         3       59.79         30       576.19         10       234.80         23       401.18 | 9       150.62       59.75 (31.09-114.84)         24       485.36       49.45 (33.14-73.77)         6       191.11       31.40 (14.10-69.88)         3       53.49       56.08 (18.09-173.89)         24       391.38       61.32 (41.10-91.49)         1       59.83       16.71 (2.35-118.66)         32       576.15       55.54 (39.28-78.54)         3       59.79       50.17 (16.18-155.56)         30       576.19       52.07 (36.40-74.47)         10       234.80       42.59 (22.92-79.15)         23       401.18       57.33 (38.10-86.27) | 9       150.62       59.75 (31.09-114.84)       1         24       485.36       49.45 (33.14-73.77)       1.02 (0.47-2.19)       0.963         6       191.11       31.40 (14.10-69.88)       1         3       53.49       56.08 (18.09-173.89)       1.96 (0.49-7.79)       0.337         24       391.38       61.32 (41.10-91.49)       2.06 (0.85-4.99)       0.111         1       59.83       16.71 (2.35-118.66)       1         32       576.15       55.54 (39.28-78.54)       3.91 (0.54-28.19)       0.177         3       59.79       50.17 (16.18-155.56)       1         30       576.19       52.07 (36.40-74.47)       1.05 (0.31-3.56)       0.931         10       234.80       42.59 (22.92-79.15)       1       1         23       401.18       57.33 (38.10-86.27)       1.66 (0.79-3.48)       0.181 |

| Combined ARV type |    |        |                       |                   |       |                   |       |
|-------------------|----|--------|-----------------------|-------------------|-------|-------------------|-------|
| DBC               | 2  | 77.48  | 25.81 (6.46-103.21)   | 1                 |       | 1                 |       |
| TBC               | 31 | 558.50 | 55.51 (39.04-78.93)   | 2.71 (0.64-11.46) | 0.176 | 2.16 (0.38-12.45) | 0.386 |
| Status disclosure |    |        |                       |                   |       |                   |       |
| Not disclosed     | 19 | 374.80 | 50.69 (32.34-79.48)   | 1                 |       | 1                 |       |
| Disclosed         | 14 | 261.18 | 53.60 (31.75-90.51)   | 1.06 (0.53-2.11)  | 0.861 | 1.20 (0.57-2.53)  | 0.628 |
| WHO stage         |    |        |                       |                   |       |                   |       |
| Stage I           | 14 | 436.16 | 32.10 (19.01-54.20)   | 1                 |       | 1                 |       |
| Stage II          | 5  | 86.69  | 57.68 (24.01-138.58)  | 1.65 (0.60-4.51)  | 0.332 | 1.53 (0.50-4.67)  | 0.454 |
| Stage III&IV      | 14 | 113.13 | 123.75 (73.29-208.95) | 3.51 (1.67-7.38)  | 0.001 | 4.63 (1.91-11.18) | 0.001 |

264 n= Sample Size, PY= Person Years, CI=Confidence Interval, Edu= Education, ZDH= Zabzugu District Hospital, TDH= Tatale District Hospital, TBC=

265 Tenofovir Based Combination, DBC= Dolutegravir Based Combination, WHO= World Health Organization

- Figure 2 presents the illustration of the hazard of mortality over the study period. The hazard of
- 267 mortality is highest between the first and the second year of follow-up but declined steadily over
- the rest of the study period from the second year on wards.
- 269



270



272

#### 273 Discussion

Preventing major AIDS-related and non-AIDS-related illnesses in HIV-infected individuals requires early initiation of antiretroviral medication [16]. The majority of the participants were initiated to ARVs at WHO stages I and II (79.31%), This was however different from what was reported in a study conducted in Ghana to assess the effects of antiretroviral therapy on all-cause of mortality among PLWH. In that study, 51.0% of PLWH were diagnosed at WHO stage I and II [17]. An expanded study involving most of the HIV sentinel sites in Ghana also found an even

lower (27.7%) prevalence of HIV initiation at WHO stage I & II [18]. The variation in findings could be due to the fact that the study was conducted during the period of the 90-90-90 treatment policy where there was a more accelerated action for HIV testing and treatment. During that period, testing was done at the OPD instead of the laboratory where only clients who were suspected of being infected were referred for testing. Providing testing services for all persons, whether symptomatic or not, meant that more clients would be diagnosed in the earlier stages of the disease.

The current study identified the majority were alive and on treatment at the end of the five years 287 of follow-up, while 34.5% were lost to follow up (LTFU) and the remaining 12.64% were dead. 288 289 Our findings were a little different from the findings in a study in a primary public hospital of Wukro, Tigray, Ethiopia, where 11% of LTFU was recorded [19]. The reason for the high rate of 290 291 LTFU could be due to the high numbers diagnosed at WHO stages I and II, who are asymptomatic and may not see the need to take their medications. Most of the fatalities occurred in the first and 292 293 second years following the start of ARVs [7]. The overall survival probabilities for the first and fifth years were 0.9376 and 0.8049, respectively. These findings, projected an improvement in 294 295 terms of survival probabilities when compared with another study conducted in Ghana in the Lawra and Jirapa districts in the upper west region where the survival probability at the end of the 296 297 three years was 0.795 per 1000 person years [7]. The findings were similar to the findings of a study conducted in the Henan province of China from 2005 to 2014 where the cumulated survival 298 299 for the first and fifth year were 93.7% and 85.3% respectively [20]. The reason for the improvement in survival probabilities could be due to the removal of all barriers to the initiation 300 301 of ARVs and early diagnosis due to the 90-90-90 policy which was not the case during the period of the study by Okyere et al., (2015). 302

Significant differences in survival probabilities were observed among specific variables using the Kaplan-Meier survival curve. WHO stages I and II had the highest survival probability and this finding agreed with studies in Ghana's upper west region and Oromiyaa, Ethiopia where WHO stages I and II had the highest survival probability than stages III and IV [7,21]. The reason for the variation among the various stages could be due to the prognosis of the disease at the time of diagnosis and initiation of the ARVs. Although disclosure of one's status may play a role in controlling the spread of HIV, it had very little impact on the improvement of the survival

probability of the clients in the short term. However, in the long term, disclosing status disclosure gives an individual a better chance of survival compared to someone who has not disclosed the status. The reason for this dynamics could be due to the support that those who disclose their status receive from their treatment supporters. Females had better survival probabilities than their male counterparts and this can be attributed to the health-seeking behaviors of females [22].

The overall mortality rate observed was low compared with what was found in a retrospective 315 cohort study from 2004-2013 in Nepal [23]. The reason for the reduction in overall mortality in 316 this study may be due to the fact that majority of the participants were diagnosed at WHO stage I 317 and II [24]. Mortality was highest among those diagnosed at the WHO stage III and IV, meaning 318 319 this group will need special attention, especially within the first two years of diagnosis where most of the deaths occurred. Regular clinic visits, viral load monitoring, and adherence to the ARV 320 321 regimen are essential to prevent mortalities. Other areas where significant variations in mortality was observed were gender and religion. Morality was high among males compared to females and 322 323 that can be attributed to the health seeking behaviors of the male gender [22].

324 The hazard of mortality after the initiation of ARVs was statistically significant and associated with those in WHO stages III and IV and age group 50<sup>+</sup> years and after adjusting in a multivariable 325 analysis, WHO stage III and IV and age group 50<sup>+</sup> years remained significant. The findings were 326 similar to other studies that were conducted in Ghana, sub-Saharan Africa, and other parts of the 327 world [7,17,21,23,25]. From the smooth hazard curve, the risk of mortality is highest in the first 328 329 and second years of ARVs initiation. More pragmatic efforts including regular clinic visits, early diagnosis of opportunistic infections, viral load monitoring and so on, are required to reduce the 330 death rate within the first and second years of ARVs initiation. 331

#### 332 Strengths and limitations

This is the first study of its kind on this subject and will contribute greatly to literature and also serve as a baseline finding for future studies. The lack of a comparison group restricted our ability to compare the outcome between those initiated on ARVs and those that are not on ARVs. Hence, comparison was done using previous studies while the presence of missing data also restricted the inclusion of variables such as viral load.

- 338
- 339

## 340 Conclusion

| 341 | Survival probabilities have improved significantly among PLWH in the two districts compared to         |
|-----|--|
| 342 | previous studies conducted before the introduction of the treat-all policy. We recommend the need      |
| 343 | for early diagnosis through testing at all entry points to hospitals and clinics and through the "Know |
| 344 | your Status" campaigns for HIV. Clients who are 50 years and above and those who were                  |
| 345 | diagnosed at the WHO stages III and IV should be given shorter clinic visit intervals and ensure       |
| 346 | viral load monitoring is done as recommended by the National AIDS Control Program.                     |
| 347 |  |
| 348 | Availability of data and materials   |
| 349 | All data are fully available without restriction   |
| 350 |  |
| 351 | Competing interests  |
| 352 | The authors declare that no competing interest existed for this study                                  |
| 353 |  |
| 354 | Funding  |
| 355 | None   |
| 356 |  |
| 357 | Author Contributions   |
| 358 | Conceptualization: ES, RNA, MMB, KB, MSY, DAO, AM, DB, EKN & AKE                                       |
| 359 | Data curation: ES, RNA, NKAB & MMB,  |
| 360 | Formal analysis: ES, RNA, MMB, KB & MSY  |
| 361 | Methodology: ES, RNA, MMB, KB, MSY, DAO, NKAB, AM, DB, EKN & AKE                                       |
| 362 | Project administration: ES, RNA, MMB, KB & MSY,  |
| 363 | Supervision: AM, DB, EKN & AKE   |
| 364 | Validation: DAO, AM, DB, EKN & AKE   |
| 365 | Writing – original draft: ES, RNA, MMB, KB & MSY   |
| 366 | Writing – review and editing: DAO, NKAB, AM, DB, EKN & AKE   |
| 367 |  |
| 368 | Acknowledgements   |
| 369 | We are grateful to all PLHIV whose records we reviewed for this study. To all the staff of the four    |
| 370 | ARVs centers in both Tatale and Zabzugu, we thank them for their efforts in saving lives and the       |

- documentation without which this study would not have been possible. We are also grateful to the
- 372 management of the two hospitals and the District Directors of Health Services for their approval
- of the study. We are most grateful to God for the inspiration, guidance and protection throughout
- the study.
- 375

## 376 **Reference**

- Owusu-ansah Y. Socio-economic effect of HIV / AIDS in Ghana. 2009;(December 2002).
   Available from: https://www.ghanaweb.com/GhanaHomePage/features/Socio-economiceffect-of-HIV-AIDS-in-Ghana-30981
- Center for Disease Control and Prevention. HIV Basics | HIV/AIDS | CDC [Internet]. 2022
   [cited 2022 Apr 6]. Available from: https://www.cdc.gov/hiv/basics/index.html
- HIV.gov. Homepage | HIV.gov [Internet]. US Department of Health and Human Services.
   2021 [cited 2021 Jul 11]. Available from: https://www.hiv.gov
- World Health Organization. HIV and AIDS [Internet]. 2023 [cited 2023 Apr 21]. Available
   from: https://www.who.int/news-room/fact-sheets/detail/hiv-aids
- 5. Ghana AIDS Commission. Ghana's HIV Fact Sheet. Off Pres Ghana. 2019;523:1–6.
- 387 6. Zolopa AR. The evolution of HIV treatment guidelines: Current state-of-the-art of ART.
  388 Antiviral Res. 2010 Jan;85(1):241–4.
- Okyere GA, Alalbil PA, Ping-Naah H, Tifere Y. Determinants of Survival in Adult HIV
   Clients on Antiretroviral Therapy in Lawra and Jirapa Districts of Upper West Region, Ghana.
   J Int Assoc Provid AIDS Care JIAPAC. 2015 May;14(3):255–60.
- Raguenaud ME, Isaakidis P, Zachariah R, Te V, Soeung S, Akao K, et al. Excellent outcomes among HIV+ children on ART, but unacceptably high pre-ART mortality and losses to followup: A cohort study from Cambodia. BMC Pediatr. 2009;9:54.
- Frank TD, Carter A, Jahagirdar D, Biehl MH, Douwes-Schultz D, Larson SL, et al. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: A systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV. 2019 Dec;6(12):e831–59.
- 10. United Nations. THE 17 GOALS | Sustainable Development [Internet]. Department of
  Economic and Social Affairs. 2018 [cited 2021 Jul 11]. Available from:
  https://sdgs.un.org/goals
- 402 11. Ghana AIDS Commission. Ghana AIDS Commission [Internet]. Ghana Aids Commission.
   403 2017. p. 1–31. Available from: https://www.ghanaids.gov.gh
   404 http://www.ghanaids.gov.gh/gac1/aids\_info.php

- 405 12. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing
  406 mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med.
  407 2013 Apr;14(4):195–207.
- 408 13. Ghana Statistical Service. Zabzugu district. 2010. 1–10 p.
- 409 14. Ghana Statistical Service. Tatale sanguli district. 2010. 1–10 p.
- 410 15. Harmon JL, Barroso J, Pence BW, Leserman J, Salahuddin N. Demographic and Illness411 Related Variables Associated with HIV-Related Fatigue. J Assoc Nurses AIDS Care JANAC.
  412 2008;19(2):90–7.
- 413 16. HIV.gov. Demographics | AHEAD [Internet]. 2023 [cited 2023 Aug 8]. Available from:
  414 https://ahead.hiv.gov/methods/demographics
- Anthony F. National Institutes of Health (NIH). 2015 [cited 2023 Mar 7]. Benefits of Early
   Antiretroviral Therapy in HIV Infection. Available from: https://www.nih.gov/news events/nih-research-matters/benefits-early-antiretroviral-therapy-hiv-infection
- 18. Dwomoh D, Tambaa C, Addo SA, Wiah E, Abdulai M, Bosomprah S. Effect of antiretroviral therapy on all-cause mortality among people living with HIV/AIDS in Ghana using Mahalanobis distant metric matching within propensity score caliper analysis: A retrospective cohort study. PLOS ONE. 2018 Sep 7;13(9):e0203461.
- 422 19. Obiri-Yeboah D, Pappoe F, Baidoo I, Arthur F, Hayfron-Benjamin A, Essien-Baidoo S, et al.
  423 Immunologic and virological response to ART among HIV infected individuals at a tertiary
  424 hospital in Ghana. BMC Infect Dis. 2018 Dec;18(1):1–7.
- 425 20. Mehari D, Mache T, Hailemariam L. Predictors of lost to follow up to antiretroviral therapy
  426 in primary public hospital of Wukro, Tigray, Ethiopia: A case control study. J AIDS HIV Res.
  427 2015 Jan 31;7(1):1–9.
- 428 21. Yao ST, Duan S, Xiang LF, Ye RH, Yang YC, Li YL, et al. [Survival analysis on 3103
  429 HIV/AIDS patients receiving antiretroviral treatment in Dehong prefecture, Yunnan province].
  430 Zhonghua Liu Xing Bing Xue Za Zhi Zhonghua Liuxingbingxue Zazhi. 2010 Nov
  431 1;31(11):1215–8.
- 432 22. Alemu AW, Sebastián MS. Determinants of survival in adult HIV patients on antiretroviral
   433 therapy in Oromiyaa, Ethiopia. Glob Health Action. 2010 Dec;3(1):5398.
- 434 23. Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K. The
  435 influence of gender and other patient characteristics on health care-seeking behaviour: a
  436 QUALICOPC study. BMC Fam Pract. 2016 Mar 31;17(1):38.
- 437 24. Angdembe MR, Rai A, Bam K, Pandey SR. Predictors of mortality in adult people living with
  438 HIV on antiretroviral therapy in Nepal: A retrospective cohort study, 2004-2013. Maiga AI,
  439 editor. PLOS ONE. 2019 Apr 23;14(4):e0215776.

440 25. Coghill AE, Han X, Suneja G, Lin CC, Jemal A, Shiels MS. Advanced Stage at Diagnosis and

- Elevated Mortality among HIV-infected US Cancer Patients in the National Cancer Database.
  Cancer. 2019 Aug 15;125(16):2868–76.
- 443 26. Mangal TD, Meireles MV, Pascom ARP, de Almeida Coelho R, Benzaken AS, Hallett TB.
  444 Determinants of survival of people living with HIV/AIDS on antiretroviral therapy in Brazil
- 445 2006-2015. BMC Infect Dis. 2019 Feb 28;19(1):206.

446